Add Yahoo as a preferred source to see more of our stories on Google. The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially preterm ...

Six recent studies conclude that maternal respiratory syncytial virus (RSV) vaccination and the long-acting monoclonal ...

Maternal RSV Vaccination Uptake Varied Sharply. MATERNAL RSV vaccination may reduce infant hospitalization, but new data from ...

An antibody treatment for respiratory syncytial virus (RSV) appears to be more effective at protecting infants from severe illness than vaccination during pregnancy. About 100,000 children worldwide ...

Maternal RSV vaccination and infant nirsevimab immunization were safe and effective when administered alone or sequentially.

Respiratory syncytial virus (RSV) is a common virus that affects the nose, throat, and lungs. For most healthy adults and children, it causes only mild, cold-like symptoms and goes away on its own.

(Reuters) -Infant hospitalizations due to respiratory syncytial virus (RSV) infections in the United States dropped as much as 43% last year compared to previous years, following the widespread ...

Surveillance captured 16,775 RSV-associated hospitalizations/ED visits; median age was 10 months, with 41% of ...

RSV is the leading cause of hospitalizations among newborns and younger children. Among those under age 5, the CDC reports between 58,000 and 80,000 hospitalizations a year. RFK Jr.'s vaccine ...

Immunising infants to protect them from the potentially serious respiratory syncytial virus (RSV) infection is safe and ...

Please provide your email address to receive an email when new articles are posted on . Only one infant with respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in the nirsevimab ...

Merck’s Enflonsia (clesrovimab) has been approved by the European Commission for the prevention of respiratory syncytial ...